Dexfenfluramine treatment and hypothalamic neuropeptides in diet-induced obesity in rats.
Neuropeptide Y (NPY) is a powerful appetite stimulant, and hypothalamic concentrations rise after food deprivation and in experimental diabetes. Serotonergic drugs such as dexfenfluramine are inhibitors of feeding. We measured hyothalamic NPY and NPY mRNA, along with galanin, neurotensin, and somatostatin in chow-fed rats and in rats with dietary obesity, and examined the effect of dexfenfluramine on these peptides in this model. Sixty-five rats were fed a palatable diet (condensed milk, sucrose and chow) for 6 weeks, which produced significant weight gain compared to twenty fed standard chow (145.1 +/- 2.3 g vs. 113.4 +/- 3.2 g, p less than 0.001). Groups of animals were treated for 7 days or 28 days with dexfenfluramine (1.8 mg/kg/day) or saline intraperitoneally via miniosmotic pumps. Hypothalami were dissected into medial and lateral blocks, and NPY, galanin, neurotensin, and somatostatin were measured by radioimmunoassay. Neuropeptide Y mRNA was measured by Northern blotting. Hypothalamic NPY was significantly higher in the palatable diet group compared to chow-fed controls (medial hypothalamus: 86.6 +/- 7.6 vs. 65.7 +/- 4.0 pmol/g tissue, p less than 0.02, lateral hypothalamus 71.2 +/- 6.6 vs. 53.1 +/- 3.6 pmol/g tissue, p less than 0.05), but NPY mRNA was unchanged. Although dexfenfluramine was effective at reducing weight gain in the animals fed the palatable diet, this did not result in any changes in the hypothalamic neuropeptides measured. Neuropeptide Y may be of importance in diet-induced obesity but the weight loss produced by dexfenfluramine in such animals is not mediated by changes in hypothalamic NPY.
Wilding
J P
JP
Division of Endocrinology and Metabolism, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Gilbey
S G
SG
Jones
P M
PM
Mannan
M M
MM
Ghatei
M A
MA
Bloom
S R
SR
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D004032:Diet; D004435:Eating / Q000502:physiology; D005277:Fenfluramine / Q000494:pharmacology*; D019004:Galanin; D007031:Hypothalamus / Q000737:chemistry* / Q000187:drug effects; D007328:Insulin / Q000097:blood; D008297:Male; D009478:Neuropeptide Y / Q000032:analysis; D009479:Neuropeptides / Q000032:analysis*; D009496:Neurotensin / Q000032:analysis; D009765:Obesity / Q000139:chemically induced / Q000378:metabolism*; D010455:Peptides / Q000032:analysis; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D011919:Rats, Inbred Strains; D013004:Somatostatin / Q000032:analysis
D001786:Blood Glucose; D007328:Insulin; D009478:Neuropeptide Y; D009479:Neuropeptides; D010455:Peptides; D012333:RNA, Messenger; D005277:Fenfluramine; D009496:Neurotensin; D013004:Somatostatin; D019004:Galanin